Valar Labs, a Palo Alto, CA-based developer of computational histology AI (CHAI) exams for predicting response to most cancers therapies, raised $22M in Collection A funding.
The spherical was led by DCVC and Andreessen Horowitz (a16z) Bio + Well being with participation from Pear VC. Vineeta Agarwala, MD, PhD, Common Companion at a16z Bio + Well being, and James Hardiman, Common Companion at DCVC, will probably be becoming a member of the Board of Administrators.
The corporate intends to make use of the funds to broaden operations and its R&D efforts.
Led by Damir Vrabac (COO), Anirudh Joshi (CEO) & Viswesh Krishna (CTO), Valar Labs is a precision drugs firm creating computational histology AI exams for predicting response to most cancers therapies. It goals to offer each affected person and doctor the power to pick the most effective therapy primarily based on the affected person’s tumor biology. Its bladder most cancers take a look at, Vesta, predicts which sufferers are unlikely to learn from BCG remedy and gives detailed danger stratification for recurrence and development.
The corporate is clinically accessible by means of its CLIA-certified laboratory in Houston, Texas and may be ordered on-line.
FinSMEs
31/05/2024
